ESLA
Estrella Immunopharma, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.74
▼ 0.00 (0.64%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.76
Prev close
0.75
Day high
0.76
Day low
0.74
Volume
8.17K
Market cap
—
P/E (TTM)
—
52W range
0.68 – 3.15
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+1.66%
+3.0%
1M
-3.80%
-7.5%
3M
-34.96%
-38.1%
6M
-37.71%
-48.8%
YTD
-52.88%
-65.2%
1Y
-18.60%
-38.6%
3Y
-91.06%
-165.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $10.25M | $4.11M | $10.45M | $1.39M | +149.4% |
| Selling, general & admin | $2.81M | $3.20M | $663.19K | $296.25K | -12.1% |
| Total operating expense | $13.06M | $7.31M | $11.11M | $1.69M | +78.7% |
| Operating income | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Pre-tax income | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Tax provision | $838 | $1.63K | $0 | $0 | -48.4% |
| Net income | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Net income to common | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Basic EPS | -0.35 | -0.27 | -0.32 | -0.05 | -29.6% |
| Diluted EPS | -0.35 | -0.27 | -0.32 | -0.05 | -29.6% |
| EBIT | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| EBITDA | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Basic shares | 36.82M | 27.10M | 35.20M | 35.20M | +35.9% |
| Diluted shares | 36.82M | 27.10M | 35.20M | 35.20M | +35.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.38M | $4.17M | $2.48M | $4.09M | -66.8% |
| Cash & short-term investments | $1.38M | $4.17M | $2.48M | $4.09M | -66.8% |
| Total current assets | $1.68M | $4.45M | $2.75M | $4.92M | -62.4% |
| Total assets | $3.18M | $4.45M | $3.03M | $4.92M | -28.7% |
| Total current liabilities | $13.54M | $180.70K | $9.76M | $946.68K | +7,394.7% |
| Total liabilities | $13.54M | $180.70K | $14.77M | $5.96M | +7,394.7% |
| Retained earnings | -$36.99M | -$19.50M | -$12.19M | -$1.07M | -89.7% |
| Shareholder equity | -$10.37M | $4.27M | -$11.74M | -$1.04M | -342.6% |
| Working capital | -$11.87M | $4.27M | -$7.01M | $3.97M | -377.7% |
| Net tangible assets | -$10.37M | $4.27M | -$11.74M | -$1.04M | -342.6% |
| Shares issued | 38.49M | 36.61M | 35.20M | 35.20M | +5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$13.06M | -$7.31M | -$11.11M | -$1.69M | -78.7% |
| Stock-based compensation | $618.97K | $1.19M | $409.60K | $129.97K | -48.2% |
| Change in working capital | $10.62M | -$9.95M | $9.37M | $113.35K | +206.7% |
| Operating cash flow | -$1.79M | -$16.07M | -$1.34M | -$1.44M | +88.9% |
| Investing cash flow | — | $4.96M | -$273.07K | $0 | — |
| Share buybacks | -$29.46K | -$354.44K | $0 | — | +91.7% |
| Financing cash flow | $2.25M | $12.79M | $0 | $5.53M | -82.4% |
| Free cash flow | -$1.79M | -$16.07M | -$1.34M | -$1.44M | +88.9% |
| End cash position | $1.38M | $4.17M | $2.48M | $4.09M | -66.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $1.40M | $25.41K | $4.15M | $4.66M | $1.41M | +5,409.9% |
| Selling, general & admin | $891.79K | $587.78K | $648.51K | $883.73K | $694.11K | +51.7% |
| Total operating expense | $2.29M | $613.20K | $4.80M | $5.54M | $2.10M | +273.8% |
| Operating income | -$2.29M | -$613.20K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Pre-tax income | -$2.29M | -$613.20K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Tax provision | $0 | -$25 | $0 | $850 | $13 | +100.0% |
| Net income | -$2.29M | -$613.17K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Net income to common | -$2.29M | -$613.17K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Basic EPS | -0.05 | — | -0.13 | -0.15 | -0.06 | — |
| Diluted EPS | -0.05 | — | -0.13 | -0.15 | -0.06 | — |
| EBIT | -$2.29M | -$613.20K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| EBITDA | -$2.29M | -$613.20K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Basic shares | 42.12M | — | 37.10M | 36.17M | 36.19M | — |
| Diluted shares | 42.12M | — | 37.10M | 36.17M | 36.19M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.93M | $1.38M | $1.63M | $1.32M | $421.47K | +39.2% |
| Cash & short-term investments | $1.93M | $1.38M | $1.63M | $1.32M | $421.47K | +39.2% |
| Total current assets | $2.16M | $1.68M | $2.02M | $1.48M | $944.27K | +28.6% |
| Total assets | $3.66M | $3.18M | $3.52M | $2.98M | $2.44M | +15.1% |
| Total current liabilities | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | -34.1% |
| Total liabilities | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | -34.1% |
| Retained earnings | -$39.28M | -$36.99M | -$36.38M | -$31.58M | -$26.03M | -6.2% |
| Shareholder equity | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | +49.2% |
| Working capital | -$6.77M | -$11.87M | -$11.34M | -$7.59M | -$3.33M | +42.9% |
| Net tangible assets | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | +49.2% |
| Shares issued | 43.18M | 38.49M | 38.28M | 37.58M | 36.68M | +12.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.29M | -$613.17K | -$4.80M | -$5.54M | -$2.10M | -273.8% |
| Stock-based compensation | $146.71K | $148.36K | $152.42K | $159.10K | $159.09K | -1.1% |
| Change in working capital | -$4.66M | $316.18K | $3.85M | $4.97M | $1.48M | -1,574.3% |
| Operating cash flow | -$6.70M | -$177.49K | -$727.33K | -$414.88K | -$465.98K | -3,673.8% |
| Share buybacks | $0 | $0 | $0 | $0 | -$29.46K | — |
| Financing cash flow | $7.24M | -$64.82K | $1.04M | $1.31M | -$29.46K | +11,270.9% |
| Free cash flow | -$6.70M | -$177.49K | -$727.33K | -$414.88K | -$465.98K | -3,673.8% |
| End cash position | $1.93M | $1.38M | $1.63M | $1.32M | $421.47K | +39.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.73
+1.06% from price
SMA 20
0.73
+0.13% from price
SMA 50
0.85
-13.28% from price
SMA 100
1.11
-33.58% from price
SMA 200
1.28
-42.76% from price
EMA 12
0.74
+0.30% from price
EMA 26
0.77
-3.76% from price
EMA 50
0.85
-13.39% from price
RSI (14)
43.3
Neutral
MACD (12,26,9)
-0.03
Hist 0.01
ATR (14)
0.06
8.44% of price
Realised vol 30D
66.2%
Annualised
Bollinger upper
0.78
20, 2σ
Bollinger lower
0.69
20, 2σ
50 / 200 cross
Death
0.85 vs 1.28
Trend bias
Below 200
-42.76%
Risk profile
Beta vs SPY
0.88
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
66.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-77.0%
Peak to trough
Max drawdown 5Y
-96.7%
Peak to trough
ATR 14
0.06
8.44% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · 12d ago
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · 20d ago
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · 25d ago
Estrella Immunopharma's Trial of EB103 to Treat Lymphoma Doses First Patient
MT Newswires · 29d ago
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Business Wire · 30d ago
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
Zacks Small Cap Research · 40d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.